- Ruxolitinib cream, a Janus kinase inhibitor, was associated with reduced itch and improved QoL for patients with atopic dermatitis (AD) in a phase 2 randomized controlled trial.
Why this matters
- AD is associated with significant pruritus and impaired QoL.
- Ruxolitinib cream 1.5% twice daily was associated with higher mean improvement rates compared with vehicle:
- Within 36 hours: 42.5% vs 13.6% (P<.01>
- At week 8: 68.5% vs 17.6% (P<.0001>
- Week 2: 63.5% vs 10.5% (P<.001>
- Week 8: 73.2% vs 19.7% (P<.001>
- 307 patients with AD with Investigator’s Global Assessment score of 2/3 and 3%-20% affected body surface area were randomly allocated to ruxolitinib cream (1.5% twice daily, 1.5% once daily, 0.5% once daily, or 0.15% once daily), vehicle twice daily, or triamcinolone cream 0.1% twice daily/vehicle for 8 weeks.
- Funding: Incyte Corporation.
- Small patient sample size in each group.
- Short trial duration.
- Facial lesions not treated.